Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 611 to 620 of 2608 total matches.
Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
insomnia
...
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Med Lett Drugs Ther. 2023 Jan 9;65(1667):e6-10 doi:10.58347/tml.2023.1667b | Show Introduction Hide Introduction
Desogestrel - A New Progestin for Oral Contraception
The Medical Letter on Drugs and Therapeutics • Aug 06, 1993 (Issue 902)
CONTRACEPTIVES
1
Estrogen (µg) µg per mg per
Drug (ethinyl estradiol) month Progestin (mg)
2
month Cost
3 ...
Desogen (Organon) and Ortho-Cept (Ortho), two oral contraceptives each containing a low dose (30 mcg) of the estrogen ethinyl estradiol plus 150 mcg of the progestin desogestrel, were recently approved by the US Food and Drug Administration for marketing in the USA. They are the first US oral contraceptives to contain desogestrel, which is widely used in oral contraceptive combination products in other countries. Desogestrel is one of three new progestins (norgestimate and gestodene are the others) considered less androgenic than previously available progestins (L Speroff et al, Obstet...
A New Testosterone Gel (Fortesta) for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Apr 18, 2011 (Issue 1362)
as a Schedule III
controlled substance. Table 1 lists some available
testosterone products, including 2 ...
The FDA has approved Fortesta (Endo), a topical gel,
for testosterone replacement therapy in adult males
with hypogonadism. It is classified as a Schedule III
controlled substance. Table 1 lists some available
testosterone products, including 2 other gels.
Casirivimab and Imdevimab (REGEN-COV) for Post-Exposure Prophylaxis of COVID-19
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
significantly less often in patients who received the
antibodies than in those who received placebo (1.5%
vs ...
The investigational monoclonal antibodies casirivimab
and imdevimab (REGEN-COV – Regeneron) have
been available in the US under an Emergency Use
Authorization (EUA) since late 2020 for use together
to treat mild to moderate COVID-19 in persons ≥12
years old who weigh ≥40 kg and are at high risk of
progression to severe disease or hospitalization. The
FDA has now expanded this EUA to allow use of the
antibodies together for post-exposure prophylaxis
of COVID-19 in such persons, if they are not fully
vaccinated against COVID-19 or are unlikely to have
an adequate immune response...
Tafenoquine (Arakoda; Krintafel) for Malaria
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
: ta fen’ oh kwin Arakoda: air’ uh koh’ duh
Krintafel: krin tah fell
Table 1. Primaquine ...
The oral antimalarial tafenoquine succinate, a long-acting
analog of primaquine, has been approved by
the FDA in 2 different strengths. Arakoda (100-mg
tablets; Sixty Degrees) is indicated for the prophylaxis
of malaria in adults. Krintafel (150-mg tablets; GSK) is
indicated for the prevention of relapse (radical cure)
of Plasmodium vivax malaria in patients ≥16 years old
undergoing treatment for acute P. vivax infection.
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024 (Issue 1693)
.............................................................................. p 1
CHA2DS2-VASc Scoring ............................................................. p 2
Oral ...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 doi:10.58347/tml.2024.1693a | Show Introduction Hide Introduction
In Brief: Absorica for Acne
The Medical Letter on Drugs and Therapeutics • Jan 21, 2013 (Issue 1408)
available for treatment of acne.1
The FDA has recently approved a new oral isotretinoin
product (Absorica ...
The oral retinoid isotretinoin (Accutane, and others) is the most effective drug available for treatment of acne.1 The FDA has recently approved a new oral isotretinoin product (Absorica – Cipher/Ranbaxy) for treatment of severe, recalcitrant nodular acne.Isotretinoin can completely clear severe nodulocystic lesions, in some cases leading to remission that can persist for years after treatment is stopped. Mucocutaneous adverse effects include dry skin, dry eye, epistaxis, nasopharyngitis, cheilitis, alopecia, eczema, skin fragility and photosensitivity. Musculoskeletal symptoms,...
In Brief: Neuropsychiatric Events with Montelukast
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
of suicidal behavior and other
serious neuropsychiatric events associated with its use.1
Montelukast ...
The FDA is requiring stronger warnings in the labeling of
the leukotriene receptor antagonist montelukast (Singulair,
and generics) about the risk of suicidal behavior and other
serious neuropsychiatric events associated with its use.
Comparison Table: Some Topical Drugs for Rosacea (online only)
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
in women
Apply once/day 481.60/30 g
637.50/30 g
Ivermectin – generic
Soolantra (Galderma)
1% cream Yes ...
View the Comparison Table: Some Topical Drugs for Rosacea
Med Lett Drugs Ther. 2024 Feb 5;66(1695):e22 doi:10.58347/tml.2024.1695c | Show Introduction Hide Introduction
Pramipexole and Ropinirole for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Nov 21, 1997 (Issue 1014)
− Permax (Athena) 1.5 to 3 mg/d divided bid or tid 158.67
Pramipexole − Mirapex (Pharmacia & Upjohn) 0.5 ...
Pramipexole (Mirapex - Pharmacia & Upjohn) and ropinirole (Requip - SmithKline Beecham), two new dopamine agonists, have been approved by the US Food and Drug Administration (FDA) for treatment of both early (without levodopa) and advanced (with levodopa) Parkinson's disease. Bromocriptine (Parlodel) and pergolide (Permax) are older dopamine agonists marketed in the USA for adjunctive use with levodopa.